MedTrace Logo

Causes of Health Disparities in African Americans With Coronary Artery Disease on Clopidogrel

NCT04619381 · Status: WITHDRAWN · Type: OBSERVATIONAL

Last updated 2021-04-01

No results posted yet for this study

Summary

African Americans with coronary artery disease who have been prescribed clopidogrel (also known as Plavix), an antiplatelet drug will be enrolled. The purpose of this study is to help identify why African Americans are at an increased risk of having a major heart attack or stroke after a common procedure to open up blocked arteries with stents. The knowledge to be gained from this study includes:

1. A better understanding of the metabolism of the antiplatelet drug, clopidogrel, and abnormal platelet function in African Americans; this understanding may provide a basis for potential future therapy
2. A better understanding of challenges to taking clopidogrel as prescribed by a doctor and opinions about a genetic test related to this medicine.

Conditions

Interventions

BEHAVIORAL

CORONARY ARTERY DISEASE AND CLOPIDOGREL: PATIENT SURVEY

Survey is a non-standardized assessment of demographics, medication compliance and reasons for non- compliance.

Sponsors & Collaborators

  • Vanderbilt University Medical Center

    lead OTHER

Principal Investigators

  • Aaron Aday, MD · VUMC

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-03-19
Primary Completion
2021-03-19
Completion
2021-03-19

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04619381 on ClinicalTrials.gov